Cornea and Anterior Segment Services, L.V. Prasad Eye Institute, Hyderabad, IndiaProf Brien Holden Eye Research Centre, L.V. Prasad Eye Institute, Hyderabad, India.
Acta Ophthalmol. 2014 Mar;92(2):167-70. doi: 10.1111/aos.12033. Epub 2013 Feb 7.
To report the results of Descemet's stripping endothelial keratoplasty (DSEK) for failed therapeutic penetrating keratoplasty (PK).
Twenty-seven eyes of 27 patients undergoing DSEK for failed therapeutic PK were analysed.
The mean age of the patients was 36 ± 13.9 years (range: 14-70 years). The median size of the therapeutic graft was 10 mm (inter-quartile range; IQR 9.5-11 mm). Descemet's membrane stripping was performed in all eyes. Graft clarity was achieved in 20/27 eyes. Six eyes had primary graft failure, and one had interface keratitis in the early postoperative period. In all eyes with primary graft failure, there was progressive stromal vascularization, which led to haziness in the graft. Late postoperative complications were rejection in four eyes, infection in two eyes, secondary graft failure in one eye and vortex keratopathy in one eye. Graft size was found to be a significant risk factor for graft rejection in this series. At the last follow-up visit, the best-corrected visual acuity was ≥20/40 in 5/27 eyes (18.5%), 20/60-20/40 in 12/27 eyes (44.4%), 20/100-20/60 in 3/27 eyes (1.5%) and ≤20/200 in 7/27 eyes (25.9%).
Considering the limited success of repeat PK in failed large therapeutic keratoplasty, DSEK is a viable option for visual rehabilitation in these eyes, however; visual acuity may be limited due to sub-epithelial/stromal or interface scarring.
报告 Descemet 膜内皮角膜移植术(DSEK)治疗失败的治疗性穿透性角膜移植(PK)的结果。
分析 27 例 27 只眼因治疗性 PK 失败而行 DSEK 的患者。
患者的平均年龄为 36±13.9 岁(范围:14-70 岁)。治疗性移植物的中位大小为 10mm(四分位间距 IQR9.5-11mm)。所有眼均行 Descemet 膜撕除。27 只眼中有 20 只眼获得了清晰的移植片。6 只眼发生原发性移植物失功,1 只眼在术后早期发生界面角膜炎。所有原发性移植物失功的眼中均有进行性基质血管化,导致移植片混浊。术后晚期并发症包括 4 只眼排斥反应、2 只眼感染、1 只眼继发性移植物失功和 1 只眼涡状角膜病变。在本系列中,移植片大小是导致移植物排斥的一个显著危险因素。末次随访时,27 只眼中有 5 只眼(18.5%)最佳矫正视力≥20/40,12 只眼(44.4%)20/60-20/40,3 只眼(1.5%)20/100-20/60,7 只眼(25.9%)≤20/200。
鉴于治疗性大角膜移植失败后重复 PK 的成功率有限,DSEK 是这些眼视力康复的可行选择,然而,由于上皮下/基质或界面瘢痕形成,视力可能受限。